NEUROONE MEDICAL TECHNOLOGIES Corp — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
NeuroOne reported Q3 FY2026 product revenue of $2.0M (up 16% YoY) with gross margins expanding to 59.9%. The company holds $11.2M in total product orders for FY2026 with $1.7M backlog as of June 30, 2026. Subsequent to quarter-end, lead investor increased stake from 7.4% to 12.5% ownership; company raised $1.0M via ATM on July 13, 2026 (400,346 shares).
Why this rating
Revenue growth and margin expansion are positive operationally, but cash burn ($4.5M decline in 9 months) and $2.0M net loss per quarter are material concerns. Backlog is encouraging relative to company size but absolute execution risk remains high.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.